Silexion Therapeutics Files 8-K on Shares and Warrants
Ticker: SLXNW · Form: 8-K · Filed: Dec 17, 2024 · CIK: 2022416
Sentiment: neutral
Topics: shares, warrants, corporate-action
Related Tickers: SLXN
TL;DR
SLXN filed an 8-K detailing ordinary shares and warrants. Check for dilution!
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on December 17, 2024, reporting on ordinary shares and warrants. The company, incorporated in the Cayman Islands, is based in Ramat-Gan, Israel, and trades on NASDAQ under the ticker SLXN.
Why It Matters
This filing provides updated information on the company's share structure and outstanding warrants, which can impact investor calculations and potential dilution.
Risk Assessment
Risk Level: low — This is a routine filing providing information on share structure and warrants, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- December 17, 2024 (date) — Date of report
- Cayman Islands (jurisdiction) — State of incorporation
- Ramat-Gan, Israel (location) — Principal executive offices
- NASDAQ (exchange) — Trading market
- SLXN (ticker) — Trading symbol
FAQ
What is the par value of Silexion Therapeutics Corp.'s ordinary shares?
The par value of the ordinary shares is $0.00001 per share.
What is the exercise price for the warrants exercisable for ordinary shares?
The exercise price for the warrants is $1.150 per share.
When was Silexion Therapeutics Corp. formerly known as Biomotion Sciences?
The company changed its name from Biomotion Sciences on May 6, 2024.
What is the principal executive office address for Silexion Therapeutics Corp.?
The principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
What is the SIC code for Silexion Therapeutics Corp.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-12-17 07:08:22
Key Financial Figures
- $0.0009 — registered Ordinary Shares, par value $0.0009 per share SLXN The Nasdaq Stock Mar
- $103.50 — Ordinary Shares at an exercise price of $103.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2432469.htm (8-K) — 48KB
- exhibit_99-1.htm (EX-99.1) — 10KB
- image00002.jpg (GRAPHIC) — 23KB
- 0001178913-24-003994.txt ( ) — 272KB
- slxn-20241217.xsd (EX-101.SCH) — 5KB
- slxn-20241217_def.xml (EX-101.DEF) — 18KB
- slxn-20241217_lab.xml (EX-101.LAB) — 27KB
- slxn-20241217_pre.xml (EX-101.PRE) — 20KB
- zk2432469_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 17, 2024, Silexion Therapeutics Corp issued a press release announcing its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy. A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated December 17, 2024 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: December 17, 2024 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer